SHORT REPORTS
Rubelia vaccination and pregnancy: preliminary report of a national survey Concern about the number ofpregnancies terminated because ofvaccination against rubella (257 in 1979-80) prompted the Department of Health and Social Security in 1981 to ask the National Congenital Rubella Surveillance Programme to study the possible teratogenicity of rubella vaccines. Evidence then available from the United States related mainly to Cendehill and HPV77-DE5 vaccines, whereas human diploid vaccine (RA 27/3), which is more immunogenic and reactogenic and therefore possibly more teratogenic, was being widely used in the United Kingdom.
Patients, methods, and results
Obstetricians have been asked to report women who either conceive within three months after vaccination against rubella or receive vaccine during pregnancy. Clinical and virological follow ups are arranged for women whose pregnancies are not terminated, and their children are followed up until 3 years of age.
By 31 May 1985, 54 mothers had been notified, 35 before and 19 after delivery. Five of them were known to the surveillance programme before the survey started, their infants (all registered as congenital rubella not confirmed) being notified because of the maternal history. Seven of the mothers were vaccinated at school (aged 13-15 years). Thirty four mothers were vaccinated before and 20 after the estimated date ofconception. The table gives the mothers' immune state before vaccination related to the strain of vaccine given and the outcome of pregnancy.
All 54 mothers delivered. One aborted spontaneously (virus was not isolated from the placenta, and rubella specific IgM was not detected in cord blood). Fifty one mothers delivered liveborn infants and two delivered stillborn infants (one was reported at necropsy as "macerated: no clear cause ofintrauterine death"; the other had "no external features of congenital rubella," but permission for necropsy was withheld). Forty four ofthe 51 liveborn infants, including two with congenital heart defects, were tested for laboratory evidence of congenital infection (presence of rubella specific IgM at birth or persistence of haemagglutination inhibition antibody beyond 8 months, or both). All tests yielded negative results. No clinical evidence of congenital rubella was found in the remaining seven infants at birth, or in three of them followed up at ages ranging from 14 months to 3 years.
Comment
Although 
Alveolitis after use of a leather impregnation spray
The use of leather impregnation sprays by the public to protect and give a waterproof finish to leather goods is becoming increasingly widespread. Respiratory distress after the use of such agents has been reported in Germany. We report the development of alveolitis after the use of a leather impregnation spray in the United Kingdom.
Case report A 17 year old youth with no history of asthma or allergy complained of severe dyspnoea and chest tightness of sudden onset; 15 minutes earlier he had used a leather impregnation agent on a pair of shoes. He was brought to the casualty department two hours later. On examination he was obese, pale, and sweaty with a temperature of 38°C, pulse 120 beats/min, sinus tachycardia, and blood pressure 130/80 mm Hg. Jugular venous pressure was not raised, and heart sounds were normal. His respiratory rate was 44 beats/min with poor expansion. Percussion note was normal, breath sounds vesicular, and air entry poor. Peak flow rate was 250 I/min, haemoglobin concentration 174 g/l, white cell count 23-5 x 109/1, and platelets 240x 109/l. Sodium concentration was 139 mmol(mEq)/l, potassium 4 9 mmol(mEq)/l, bicarbonate 23 mmol(mEq)/l, and urea 6-5 mmol/l (39 mg/100 ml). Arterial pH in room air was 7-36, carbon dioxide tension 4-5 kPa (34 mmHg), oxygen tension 7-9 kPa (59 mmHg), bicarbonate 19 mmolJI, oxygen saturation 90%, base deficit 4-9 mmol(mEq)/l. An electrocardiogram showed sinus tachycardia, and chest radiography showed widespread patchy changes (figure).
Immune state before vaccination, strain ofvacine given, and outcome ofpregnancy Chest x ray film on admission.
Alveolitis was diagnosed, and he was started on hydrocortisone 200 mg six hourly intravenously and 35% oxygen by facemask. Twelve hours later he was considerably better. Oral steroids were continued for five days, after which time he was asymptomatic and a chest radiograph was normal.
Comment
Inhalation of various organic and inorganic substances can cause alveolitis. Pulmonary distress after the use of leather impregnation sprays in homes has been reported in the Federal Republic of Germany.'2 The development of alveolitis in our patient, however, was intriguing as the previously reported cases occurred at a time when the formulation of the product had been slightly modified, and toxic effects have not been noted since the original formula was reinstated.
The constituent of the spray that is responsible for these effects is difficult to identify: the constituents are not named on the can, and the manufacturer is not able to give further details. The toxicity of the fluorocarbons used as propellants in the aerosols has long been known but usually takes the form of cardiotoxicity.3 The active constituents vary in their properties but. essentially consist of perfluorocarbon polymers, which are hydrophilic molecules that bind strongly to the substrate. These perfluorocarbon polymers probably also act like a surfactant in the alveolar region.4 Disruption of the alveolar surfactant is important in the adult respiratory distress syndrome and has been implicated after inhalation of lipid aerosols.5
The importance of prompt treatment with steroids was emphasised by Schicht et al, who described five patients who developed respiratory distress after using leather impregnation sprays.' All five patients had abnormalities of ventilation and diffusion as well as pronounced radiological changes; four had considerable leucocytosis. Pulmonary fibrosis developed in one patient who was untreated but not in the four who received prompt treatment with steroids.
It is important to be aware of this potential toxicity of leather impregnation sprays, which militates against their continued use in the home. Prompt steroid treatment is vital if long term complications are to be avoided.
We thank Dr I D Ramsay, Dr G S Rai, and Mr D Cambridge for guidance and criticisms, and Ms L C Scott, who typed the manuscript. 
Serious interaction between cyclosporin A and sulphadimidine
Immunosuppression with cyclosporin A is now the treatment of choice in many transplant centres. Though the "window" of therapeutic activity, as assessed by blood concentrations of the drug, is still a matter of debate, it is undoubtedly true that low or undetectable blood concentrations may lead to graft rejection in the early postoperative period.' We report five cases in which interaction between sulphadimidine and cyclosporin resulted in inadequate cyclosporin immunosuppression. One of these patients has been reported on briefly elsewhere.2
Case reports
Three men and two women aged between 27 and 51 years who had undergone orthotopic cardiac transplantation contracted Pneumocystis carnnii pneumonia three to six months postoperatively. Three patients with cough and breathlessness had bilateral inspiratory crackles on auscultation and were hypoxaemic breathing air. Two were asymptomatic with no abnormal examination findings and normal arterial blood gas tensions. All had diffuse bilateral shadowing in chest radiographs. In four patients the diagnosis was confirmed by histological examination of transbronchial biopsy material. In the fifth a rising antibody titre to Pneumocystis was detected.
Each patient had been immunosuppressed with cyclosporin A since operation and on admission was receiving 300-400 mg by mouth twice daily. All had a raised blood urea concentration (mean 15-0 (SEM 1-0) mmol/l; 90 4 (6 0) mg/l00 ml). Cyclosporin A was continued and intravenous sulphadimidine 1-2 g six hourly and trimethoprim 120-800 mg twice daily begun. The dose of trimethoprim was adjusted to maintain a serum trimethoprim concentration between 5 and 10 mg/Il. Five to 24 days later (mean 11 days) oral treatment with co-trimoxazole (80 mg trimethoprim, 400 mg sulphamethoxazole) in a dose of 8-16 tablets daily was substituted for intravenous trimethoprim and sulphadimidine. This dose was also adjusted according to the serum trimethoprim concentration.
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